HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice (Q37608527)

21 August 2017

title

HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice (English)

1 reference

21 August 2017

1 reference

Issam Zineh

1

1 reference

21 August 2017

publication date

1 March 2005

1 reference

21 August 2017

1 reference

21 August 2017

volume

1

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

191-206

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Genetic polymorphisms and statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholester

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Lipoprotein lipase: structure, function, regulation, and role in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Dynamics of reverse cholesterol transport: protection against atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Cholesteryl ester transfer protein and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Nucleotide sequence and structure of the human apolipoprotein E gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Apolipoprotein E and atherosclerosis: insight from animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The APOE locus and the pharmacogenetics of lipid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796678.1.2.191

21 January 2018

Identifiers

DOI

10.1517/14796678.1.2.191

1 reference

21 August 2017

1 reference